Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer
PD-(L)1 inhibitors and anlotinib has promising efficacy and manageable toxicity as the second-line therapy of ES-SCLC.
Authors
- Yuping Sun (ORCID: https://orcid.org/0000-0002-0804-6850)
- Juan Li (ORCID: https://orcid.org/0000-0002-0992-2699)
- Aiqin Gao (ORCID: https://orcid.org/0009-0009-3596-6669)
- Jiän Zhang (ORCID: https://orcid.org/0000-0002-0557-886X)
- Jiake Wu
- Dahai Wang (ORCID: https://orcid.org/0000-0001-5488-4831)
- Shuyun Wang (ORCID: https://orcid.org/0009-0000-2519-8875)
- Qinglei Cheng
- Zijie Wu (ORCID: https://orcid.org/0000-0002-7378-3726)
- Haifeng Sun (ORCID: https://orcid.org/0000-0003-4654-9237)
- Yihui Ge
- Yanxin Sun
Institutions
- Weifang Medical University (CN)
- Shandong University (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12885-025-14458-5
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Wu Jieping Medical Foundation